{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:27:55Z","timestamp":1791350875320,"version":"4.3.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,1,9]],"date-time":"2009-01-09T00:00:00Z","timestamp":1231459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00134-008-1383-2","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T13:29:17Z","timestamp":1231421357000},"page":"603-612","source":"Crossref","is-referenced-by-count":59,"title":["Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU"],"prefix":"10.1007","volume":"35","author":[{"given":"Isabel","family":"Spriet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Meersseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Hoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrina","family":"von Winckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,9]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CCM.0000198106.54306.D7","volume":"34","author":"BJ Kopp","year":"2006","unstructured":"Kopp BJ, Erstad BL, Allen ME, Theodorou AA, Priestley G (2006) Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 34:415\u2013425","journal-title":"Crit Care Med"},{"key":"1383_CR2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0272-5231(03)00096-0","volume":"24","author":"V Krishnan","year":"2003","unstructured":"Krishnan V, Murray P (2003) Pharmacologic issues in the critically ill. Clin Chest Med 24:671\u2013688","journal-title":"Clin Chest Med"},{"key":"1383_CR3","volume-title":"Stockley\u2019s drug interactions","author":"K Baxter","year":"2006","unstructured":"Baxter K, Stockley IH (2006) Stockley\u2019s drug interactions, 7th edn. Pharmaceutical Press, London","edition":"7"},{"key":"1383_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.282.3.267","volume":"281","author":"LL Leape","year":"1999","unstructured":"Leape LL, Cullen DJ, Dempsey Clapp M, Burdick E, Demonaco HJ, Ives Erickson J, Bates DW (1999) Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 281:267\u2013270","journal-title":"JAMA"},{"key":"1383_CR5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.2146\/ajhp060641","volume":"64","author":"A Rivkin","year":"2007","unstructured":"Rivkin A (2007) Admission to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 64:1840\u20131843","journal-title":"Am J Health Syst Pharm"},{"key":"1383_CR6","first-page":"62","volume":"6","author":"MJ Ellenhorn","year":"1996","unstructured":"Ellenhorn MJ, Sternad FA (1996) Problems of drug interactions. J Am Pharmacol Assoc NS 6:62\u201368","journal-title":"J Am Pharmacol Assoc NS"},{"key":"1383_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0300-483X(03)00247-6","volume":"192","author":"M Pirmohamed","year":"2003","unstructured":"Pirmohamed M, Park BK (2003) Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicol 192:23\u201332","journal-title":"Toxicol"},{"key":"1383_CR8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccc.2006.02.004","volume":"22","author":"HJ Mann","year":"2006","unstructured":"Mann HJ (2006) Drug-associated disease: cytochrome P450 interactions. Crit Care Clin 22:329\u2013345","journal-title":"Crit Care Clin"},{"key":"1383_CR9","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211\u20132221","journal-title":"N Engl J Med"},{"key":"1383_CR10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/phgs.5.3.305.29827","volume":"5","author":"DF Lewis","year":"2004","unstructured":"Lewis DF (2004) 57 varieties: the human cytochromes P450. Pharmacogenom 5:305\u2013318","journal-title":"Pharmacogenom"},{"key":"1383_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","volume":"35","author":"JH Lin","year":"1998","unstructured":"Lin JH, Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361\u2013390","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR12","first-page":"602","volume":"8","author":"KM Kulmatycki","year":"2005","unstructured":"Kulmatycki KM, Jamali F (2005) Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharmaceut Sci 8:602\u2013625","journal-title":"J Pharm Pharmaceut Sci"},{"key":"1383_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1389200043335559","volume":"5","author":"KW Renton","year":"2004","unstructured":"Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235\u2013243","journal-title":"Curr Drug Metab"},{"key":"1383_CR14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","volume":"38","author":"K Venkatakrishnan","year":"2000","unstructured":"Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 38:111\u2013180","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT (2003) Pharmacokinetic interactions with rifampicin. Clinical relevance. Clin Pharmacokinet 42:819\u2013850","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR16","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","volume":"162","author":"CK Finch","year":"2002","unstructured":"Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions. An update. Arch Intern Med 162:985\u2013992","journal-title":"Arch Intern Med"},{"key":"1383_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00042737-200105000-00025","volume":"13","author":"LB Gerson","year":"2001","unstructured":"Gerson LB, Triadafilopoulos G (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13:611\u2013616","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1383_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, H\u00e4ussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61\u201398","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2710.1999.00201.x","volume":"24","author":"E Tanaka","year":"1999","unstructured":"Tanaka E (1999) Clinically significant pharmacokinetic drug interactions between anti-epileptic drugs. J Clin Pharm Ther 24:87\u201389","journal-title":"J Clin Pharm Ther"},{"key":"1383_CR20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2005","unstructured":"Perucca E (2005) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246\u2013255","journal-title":"Br J Clin Pharmacol"},{"key":"1383_CR21","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.mcna.2006.06.008","volume":"90","author":"MP Pai","year":"2006","unstructured":"Pai MP, Momary KM, Rodvold KA (2006) Antibiotic drug interactions. Med Clin N Am 90:1223\u20131255","journal-title":"Med Clin N Am"},{"key":"1383_CR22","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","volume":"26","author":"AH Saad","year":"2006","unstructured":"Saad AH, DePestel D, Carver P (2006) Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26:1730\u20131744","journal-title":"Pharmacotherapy"},{"key":"1383_CR23","volume-title":"Concise guide to drug interaction principles for medical practice","author":"KL Cozza","year":"2003","unstructured":"Cozza KL, Armstrong SC, Oesterheld JR (2003) Concise guide to drug interaction principles for medical practice, 2nd edn. American Psychiatric Publishing, Washington, DC","edition":"2"},{"key":"1383_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41\u201357","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","volume":"41","author":"MM Doherty","year":"2002","unstructured":"Doherty MM, Charman WH (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism. Clin Pharmacokinet 41:235\u2013253","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","volume":"54","author":"JT Backman","year":"1998","unstructured":"Backman JT, Kivist\u00f6 KT, Olkkola KT, Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53\u201358","journal-title":"Eur J Clin Pharmacol"},{"key":"1383_CR27","first-page":"511","volume":"82","author":"KT Olkkola","year":"1996","unstructured":"Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511\u2013516","journal-title":"Anesth Analg"},{"key":"1383_CR28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649\u2013663","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","volume":"64","author":"JC Gorski","year":"1998","unstructured":"Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O\u2019Mara EM, Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133\u2013143","journal-title":"Clin Pharmacol Ther"},{"key":"1383_CR30","first-page":"400","volume":"34","author":"RA Yeates","year":"1996","unstructured":"Yeates RA, Laufen H, Zimmermann T (1996) Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 34:400\u2013405","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1383_CR31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1034\/j.1399-6576.1999.430504.x","volume":"43","author":"J Ahonen","year":"1999","unstructured":"Ahonen J, Olkkola KT, Takala A, Neuvonen PJ (1999) Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 43:509\u2013514","journal-title":"Acta Anaesthesiol Scand"},{"key":"1383_CR32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","volume":"37","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkolla KT, Ojala M, Laaksovirta H, Neuvonen PJ (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253\u2013257","journal-title":"Epilepsia"},{"key":"1383_CR33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","volume":"59","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7\u201313","journal-title":"Clin Pharmacol Ther"},{"key":"1383_CR34","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM200005183422002","volume":"342","author":"JP Kress","year":"2000","unstructured":"Kress JP, Pohlman AS, O\u2019Connor MF, Hall JB (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342:1471\u20131477","journal-title":"N Engl J Med"},{"key":"1383_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bmt.1704316","volume":"33","author":"HL Leather","year":"2004","unstructured":"Leather HL (2004) Drug interactions in the hematopoetic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marr Transplant 33:137\u2013152","journal-title":"Bone Marr Transplant"},{"key":"1383_CR36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813\u2013851","journal-title":"Clin Pharmacokinet"},{"key":"1383_CR37","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1345\/aph.1C117","volume":"36","author":"RB Ibrahim","year":"2002","unstructured":"Ibrahim RB, Abella EM, Chandrasekar PH (2002) Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation. Ann Pharmacother 36:1971\u20131972","journal-title":"Ann Pharmacother"},{"key":"1383_CR38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(94)92383-3","volume":"344","author":"C Jensen","year":"1994","unstructured":"Jensen C, Jordan M, Shapiro R, Scantlebury V, Hakala T, Fung J, Starzl T, Venkataramanan R (1994) Interaction between tacrolimus and erythromycin. Lancet 344:825","journal-title":"Lancet"},{"key":"1383_CR39","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1086\/516138","volume":"25","author":"DL Paterson","year":"1997","unstructured":"Paterson DL, Singh N (1997) Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 25:1430\u20131440","journal-title":"Clin Infect Dis"},{"key":"1383_CR40","unstructured":"Vfend (voriconazole) package insert. Pfizer Inc. January 2006"},{"key":"1383_CR41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mcp.2002.121911","volume":"71","author":"AJ Romero","year":"2002","unstructured":"Romero AJ, Pogamp PL, Nilsson LG, Wood N (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71:226\u2013234","journal-title":"Clin Pharmacol Ther"},{"key":"1383_CR42","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00007890-199105000-00016","volume":"51","author":"DM Canafax","year":"1991","unstructured":"Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ (1991) Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51:1014\u20131018","journal-title":"Transplantation"},{"key":"1383_CR43","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/00007890-199705150-00015","volume":"63","author":"JM Aguado","year":"1997","unstructured":"Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, Moreno A, Gurgui A, Hayek M, Lumbreras C, and the Spanish Transplantation Infection Study Group, GESITRA (1997) Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 63:1276\u20131286","journal-title":"Transplantation"},{"key":"1383_CR44","first-page":"121","volume":"94","author":"Z Karasu","year":"2001","unstructured":"Karasu Z, Gurakar A, Carlson J, Pennington S, Kerwin B, Wright H, Nour B, Sebastian A (2001) Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. J Okla State Med Assoc 94:121\u2013123","journal-title":"J Okla State Med Assoc"},{"key":"1383_CR45","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0041-1345(00)00996-9","volume":"32","author":"GE McLaughlin","year":"2000","unstructured":"McLaughlin GE, Gonzalez-Rossique M, Gelman B, Kato T (2000) Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant Proc 32:665\u2013668","journal-title":"Transplant Proc"},{"key":"1383_CR46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.psy.44.2.167","volume":"44","author":"SC Armstrong","year":"2003","unstructured":"Armstrong SC, Cozza KL (2003) Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part I. Psychosomatics 44:167\u2013171","journal-title":"Psychosomatics"},{"key":"1383_CR47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1176\/appi.psy.44.6.515","volume":"44","author":"SC Armstrong","year":"2003","unstructured":"Armstrong SC, Cozza L (2003) Pharmacokinetic drug interactions of morphine, codeine and their derivatives: theory and clinical reality, Part II. Psychosomatics 44:515\u2013520","journal-title":"Psychosomatics"},{"key":"1383_CR48","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0749-0704(18)30298-7","volume":"7","author":"ML Buck","year":"1991","unstructured":"Buck ML, Blumer JL (1991) Opioids and other analgesics. Adverse effects in the intensive care unit. Crit Care Clin 7:615\u2013637","journal-title":"Crit Care Clin"},{"key":"1383_CR49","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/bja\/81.4.598","volume":"81","author":"VJ Palkama","year":"1998","unstructured":"Palkama VJ, Neuvonen PJ, Olkolla KT (1998) The CYP3A4 inhibitor itraconazole has no effect on the pharmacokinetics and pharmacodynamics of i.v. fentanyl. Br J Anaesth 81:598\u2013600","journal-title":"Br J Anaesth"},{"key":"1383_CR50","doi-asserted-by":"crossref","first-page":"A594","DOI":"10.1097\/00000542-198809010-00594","volume":"69","author":"R Tempelhoff","year":"1988","unstructured":"Tempelhoff R, Modica P, Spitznagel E (1988) Increased fentanyl requirement in patients receiving long-term anticonvulsant therapy. Anesthesiology 69:A594","journal-title":"Anesthesiology"},{"key":"1383_CR51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2165\/00023210-200418150-00004","volume":"18","author":"R Beers","year":"2004","unstructured":"Beers R, Camporesi E (2004) Remifentanil update: clinical science and utility. CNS Drugs 18:1085\u20131104","journal-title":"CNS Drugs"},{"key":"1383_CR52","first-page":"1165","volume":"15","author":"H Linthoudt","year":"1996","unstructured":"Linthoudt H, Van Raemdonck D, Lerut T, Demedts M, Verleden G (1996) The association of itraconazole and methylprednisolone may give rise to important steroid-related side effects. J Heart Lung Transplant 15:1165","journal-title":"J Heart Lung Transplant"},{"key":"1383_CR53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/clpt.1987.173","volume":"42","author":"M Bartoszek","year":"1987","unstructured":"Bartoszek M, Brenner AM, Szefler SJ (1987) Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 42:424\u2013432","journal-title":"Clin Pharmacol Ther"},{"key":"1383_CR54","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","volume":"351","author":"WA Ray","year":"2004","unstructured":"Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351:1089\u20131096","journal-title":"N Engl J Med"},{"key":"1383_CR55","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1056\/NEJMp048192","volume":"351","author":"BA Liu","year":"2004","unstructured":"Liu BA, Juurlink DN (2004) Drug and the QT interval\u2014Caveat Doctor. N Engl J Med 351:1053\u20131056","journal-title":"N Engl J Med"},{"key":"1383_CR56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/infdis\/171.3.747","volume":"171","author":"RJ Wallace","year":"1995","unstructured":"Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K (1995) Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium\u2013M. intracellulare infection. J Infect Dis 171:747\u2013750","journal-title":"J Infect Dis"},{"key":"1383_CR57","first-page":"365","volume":"156","author":"S Telt","year":"1992","unstructured":"Telt S, Carey D, Lee HS (1992) Drug interactions with fluconazole. Med J Aust 156:365","journal-title":"Med J Aust"},{"key":"1383_CR58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.49","volume":"49","author":"RA Blum","year":"1991","unstructured":"Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrisson NJ, Schentag JJ (1991) Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 49:420\u2013425","journal-title":"Clin Pharmacol Ther"},{"key":"1383_CR59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archinte.162.4.405","volume":"162","author":"DA Flockhart","year":"2002","unstructured":"Flockhart DA, Tanus-Santos JE (2002) Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 162:405\u2013412","journal-title":"Arch Intern Med"},{"key":"1383_CR60","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 1 December 2007. Developed by the DHHS Panel on antiretroviral guidelines for adults and adolescents\u2014a working group of the office of AIDS research advisory council (OARAC). Available from: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf . Accessed on: 15 January 2008"},{"key":"1383_CR61","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007691-199412000-00015","volume":"16","author":"DM Burger","year":"1994","unstructured":"Burger DM, Meenhorst PL, Mulder JW, Kraaijeveld CL, Koks CHW, Bult A, Bijnen JH (1994) Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome. Ther Drug Monit 16:616\u2013620","journal-title":"Ther Drug Monit"},{"key":"1383_CR62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/j.1552-4604.1988.tb03139.x","volume":"28","author":"GT Blyden","year":"1988","unstructured":"Blyden GT, Scavone JM, Greenblatt DJ (1988) Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 28:240\u2013245","journal-title":"J Clin Pharmacol"},{"key":"1383_CR63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.1985.tb05071.x","volume":"20","author":"L Kay","year":"1985","unstructured":"Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JEM, Skovsted L, Kristenen M (1985) Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 20:323\u2013326","journal-title":"Br J Clin Pharmacol"},{"key":"1383_CR64","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, Mc Donald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095\u20131106","journal-title":"Arch Intern Med"},{"key":"1383_CR65","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","volume":"147","author":"DS Budnitz","year":"2007","unstructured":"Budnitz DS, Shehab N, Kegler SR, Richards CL (2007) Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147:755\u2013765","journal-title":"Ann Intern Med"},{"key":"1383_CR66","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1592\/phco.28.9.1084","volume":"28","author":"NA Limdi","year":"2008","unstructured":"Limdi NA, Veenstra DL (2008) Warfarin pharmacogenetics. Pharmacother 28:1084\u20131087","journal-title":"Pharmacother"},{"key":"1383_CR67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","volume":"358","author":"UI Schwarz","year":"2008","unstructured":"Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999\u20131008","journal-title":"N Engl J Med"},{"key":"1383_CR68","unstructured":"US Food and Drug Administration. Warfarin product labelling. Available from http:\/\/www.fda.gov\/cder\/foi\/label\/2007\/009218s105lblv2.pdf Accessed 1 September 2008"},{"key":"1383_CR69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","volume":"19","author":"S Ozawa","year":"2004","unstructured":"Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1. Drug Metab Pharmacokinet 19:83\u201395","journal-title":"Drug Metab Pharmacokinet"},{"key":"1383_CR70","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1213\/ane.0b013e31817b796e","volume":"107","author":"UM Stamer","year":"2008","unstructured":"Stamer UM, St\u00fcber F, Muders T, Musshoff F (2008) Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 107:926\u2013929","journal-title":"Anesth Analg"},{"key":"1383_CR71","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","volume":"351","author":"Y Gashe","year":"2004","unstructured":"Gashe Y, Daaili Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827\u20132837","journal-title":"N Engl J Med"},{"key":"1383_CR72","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","volume":"368","author":"G Koren","year":"2006","unstructured":"Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine prescribed mother. Lancet 368:704","journal-title":"Lancet"},{"key":"1383_CR73","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0735-6757(95)90185-X","volume":"13","author":"BP Skop","year":"1995","unstructured":"Skop BP, Brown TM, Mareth TR (1995) The serotonin syndrome associated with paroxetine. Am J Emerg Med 13:606\u2013607","journal-title":"Am J Emerg Med"},{"key":"1383_CR74","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2146\/ajhp060414","volume":"64","author":"LA Kroon","year":"2007","unstructured":"Kroon LA (2007) Drug interactions with smoking. Am J Health Syst Pharm 64:1917\u20131921","journal-title":"Am J Health Syst Pharm"},{"key":"1383_CR75","unstructured":"Mouly S, Meune C, Bergmann JF (2007) Application and clinical value of in vitro models in predicting CYP-mediated drug\u2013drug interactions in the ICU. I. Basic Science (accepted)"},{"key":"1383_CR76","unstructured":"US Food and Drug Administration. Center for Devices and Radiological Health consumer information. New device clearance. Roche Amplichip cytochrome P450 genotyping test and Affymetrix GeneChip Microarray Instrumentation System\u2014K042259. Available from: http:\/\/www.fda.gov\/cdrh\/mda\/docs\/k042259.html Accessed 16 September 2008"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-008-1383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-008-1383-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-008-1383-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:53:26Z","timestamp":1558616006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-008-1383-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,9]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s00134-008-1383-2","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,9]]}}}